By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Lymphoid Tissue are discussed in a new report. According to news reporting originating in Penrith, Australia, by NewsRx journalists, research stated, "The aim of this study was to evaluate the biodistribution of dextran-coated iron oxide nanoparticles labeled with gallium-67 (Ga-67) in various organs by intravenous injection in Balb/c mice.Methods Ultrasmall superparamagnetic iron oxide (USPIO) was successively labeled with Ga-67-chloride after chelation with freshly prepared cyclic DTPA-dianhydride. The labeling efficiency of USPIOs labeled with Ga-67 is above 98%."
The news reporters obtained a quote from the research from the University of Western Sydney, "Sixty-five mice were killed at 13 different time points. The percentage of injected dose per gram of each organ was measured by direct counting for 19 harvested organs of the mice. The medical internal radiation dose formula was applied to extrapolate data from mouse to human and to predict the absorbed radiation dose for various organs in the human body.Results The biodistribution of Ga-67-USPIO in Balb/c mice showed that 75% of the injected dose accumulated in the spleen and liver 15 min after injection. These nanoparticles remained in the liver for more than 7 days after injection, whereas their clearance was very fast from other organs."
According to the news reporters, the research concluded: "Extrapolating these data to the intravenous injection of Ga-67-USPIO in humans gave an estimated absorbed dose of 36.38 mSv/MBq for the total body, and the highest effective absorbed dose was seen in the liver (32.9 mSv/MBq).Conclusion High uptakes of USPIO nanoparticles in the liver and spleen and their fast clearance from other tissues suggest that these nanoparticles labeled with a -emitter radioisotope could be suitable as treatment agents for spleen and liver malignancies only if the organ tolerance dose is not exceeded."
For more information on this research see: Estimated background doses of [Ga-67]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers. Nuclear Medicine Communications, 2013;34(9):915-925. Nuclear Medicine Communications can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins - www.lww.com; Nuclear Medicine Communications - journals.lww.com/nuclearmedicinecomm/pages/default.aspx)
Our news correspondents report that additional information may be obtained by contacting S. Shanehsazzadeh, University of Western Sydney, Sch Med, Canc Pathol & Cell Biol Lab, Penrith, NSW 1797, Australia. Additional authors for this research include M.A. Oghabian, A. Lahooti, M. Abdollahi, S.A. Haeri, M. Amanlou, F.J. Daha and B.J. Allen (see also Lymphoid Tissue).
Keywords for this news article include: Cancer, Spleen, Penrith, Oncology, Nanoparticle, Therapeutics, Nanotechnology, Lymphoid Tissue, Emerging Technologies, Hemic and Immune Systems, Australia and New Zealand
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC